Wedoany.com Report-Dec.22, GSK plc has concluded an agreement with the United States government to reduce the costs of certain prescription medicines for patients in the country, particularly those in its respiratory portfolio used to treat conditions such as asthma and chronic obstructive pulmonary disease affecting over 40 million individuals.

The arrangement includes commitments to lower prices for selected medicines supplied through the Medicaid program and to introduce future products with pricing that reflects contributions from various developed nations.

The terms extend to both GSK and its affiliate ViiV Healthcare, offering a clear outlook on the upcoming pricing structure in the United States. In addition, the agreement grants exemption from section 232 tariffs for a period of three years for both entities.

As part of efforts to strengthen domestic supply chain stability for essential medicines, GSK will secure a reserve of albuterol, the active ingredient commonly used in inhalers for managing asthma and COPD symptoms.

Building on its established approach to responsible pricing globally, GSK will make the majority of its inhaled respiratory treatments and additional products accessible through a direct purchasing platform, providing patients with potential savings of up to 66 percent.

Emma Walmsley, Chief Executive Officer of GSK, stated: "Today's announcement builds on GSK's strong track record of increasing access and improving the affordability of its medicines worldwide, including an ongoing commitment to responsible pricing.

"GSK has been at the forefront of respiratory innovation for decades – helping millions of Americans prevent and treat chronic respiratory diseases such as asthma and COPD. Through this agreement, GSK will ensure patients have access to the current portfolio of respiratory medicines while bringing the next wave of innovation to American patients."

This collaboration supports continued investment in research, development, and manufacturing within the United States, aligning with broader objectives to enhance medicine availability and supply reliability.